CNSP News and Press, CNS Pharmaceuticals Inc. From 03/29/22

Texas-based CNS Pharmaceuticals is a novel brain cancer drug developer that is building a series of global clinical trials for its lead drug candidate, Berubicin CNS began dosing patients in a global trial last September to evaluate Berubicin in treating glioblastoma multiforme (“...

The National Institutes of Health, under the National Cancer Institute, recently unveiled a new initiative that will provide biomarker testing to young adults, adolescents and children who have been diagnosed with tumors afflicting the central nervous system. The tests will be offered to p...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate at the 2022 Virtu...

CNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest PR Newswire Live webcast fireside chat on Wednesday, March 30 th at 2:30 PM ET HOUSTON , March 23, 2022 /PRNewsw...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. The company’s CEO ...

A new study has found that young men have a heightened risk of death from central nervous system cancer regardless of the cancer treatment they undergo . Central nervous system cancer is one of the top five cancers diagnosed in young adults. It develops when... Read more » NOT...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today released a video to shareholders that reiterates its operational and c...

CNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to Shareholders Video from John Climaco, CEO of CNS Pharmaceuticals now available on the Company's website PR Newswire HOUSTON , March 9, 2022 /PRNewswire/ ...

The National Brain Tumor Society and Yale University have partnered to conduct research on response mechanisms for DNA damage in an attempt to find new treatments for brain tumor patients. The National Brain Tumor Society is the biggest not-for-profit organization focused on brain cancer i...

The company also participated in the H.C. Wainwright BioConnect Conference earlier in January CNS Pharmaceuticals recently received approval from swissethics for a pivotal Berubicin and GBM clinical trial The five-year survival rate for GBM is only 6.8%, with the average patient popul...